18 research outputs found
Sputum culture positive by week in MGIT system, N = 25.
<p>All patients (100%) culture positive from pretreatment sputum specimen.</p
Change in plasma drug activity measured at the time of estimated peak concentration (2hr) after 2 and 4 weeks of treatment.
<p>TDA = Tuberculosis drug activity, where values greater than 1.0 indicate <i>in vitro</i> killing of a patient’s plasma against their own <i>M</i>. <i>tuberculosis</i> isolate. p = 0.005 by paired sample t-test.</p
Clinical characteristics, patients treated for pulmonary multidrug-resistant tuberculosis (MDR-TB), N = 25.
<p><sup>a</sup>At MDR-TB treatment initiation.</p><p>Clinical characteristics, patients treated for pulmonary multidrug-resistant tuberculosis (MDR-TB), N = 25.</p
Predictors of favorable interim treatment outcome using exact logistic regression.
<p><sup>a</sup>Greater change in time-to-positivity (TTP) reflects greater decrement in sputum bacterial burden.</p><p>Predictors of favorable interim treatment outcome using exact logistic regression.</p
Comparison of patients that completed intensive phase of MDR-TB therapy to those that died.
*<p>Excludes 3 patients that defaulted.</p>†<p>Excludes 8 patients for whom follow-up sputum culture results unavailable.</p><p>N/a =  not applicable.</p
Prevalence of medication related symptoms.
<p>The prevalence of medication related symptoms during the inpatient intensive phase occurring at least once in an individual patient, as determined by percentage of total patients (N = 61).</p
Demographics and pretreatment characteristics, N = 74.
<p>Demographics and pretreatment characteristics, N = 74.</p
Distribution of the time to sputum culture conversion.
<p>Legend: Sputum was collected for culture prior to treatment initiation and monthly thereafter. Culture conversion was defined as the first of two consecutive months of negative cultures. Eight subjects were excluded as regular follow-up culture results were unavailable.</p
Patients referred to KNTH for MDR-TB treatment.
<p>KNTH =  Kibong’oto National TB Hospital, Tanzania. MDR-TB =  multidrug-resistant tuberculosis. All patients had pulmonary TB.</p
Rifabutin MIC distribution stratified among conventional rifampin-susceptible and rifampin-resistant isolates.
<p>Conventional rifampin susceptible by APM (agar proportion method) critical concentration (MIC≤1.0 μg/ml) and resistance (MIC >1.0 μg/ml). Rifabutin critical concentration = 0.5 μg/ml; susceptible (<0.25 μg/ml), borderline susceptible (0.25–0.5 μg/ml), borderline resistant (1.0–2.0 μg/ml) and resistant (>2.0 μg/ml). Percentages of N within each category of rifampin susceptible and resistant.</p